From 5146e0df8b062b0310a23856f86b618160d218fd Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 22 Apr 2026 07:27:18 +0000 Subject: [PATCH] vida: extract claims from 2026-04-22-kff-medicare-glp1-bridge-lis-exclusion - Source: inbox/queue/2026-04-22-kff-medicare-glp1-bridge-lis-exclusion.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...re-inverts-need-creating-equity-paradox.md | 7 +++ ...e-within-28-52-weeks-of-discontinuation.md | 21 +++---- ...tructurally-denies-lowest-income-access.md | 18 ++++++ ...rchitecture-creates-2027-coverage-cliff.md | 19 +++++++ .../health/medicare-glp1-bridge-program.md | 57 +++++++++++++++++++ 5 files changed, 112 insertions(+), 10 deletions(-) create mode 100644 domains/health/medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access.md create mode 100644 domains/health/medicare-glp1-bridge-temporary-architecture-creates-2027-coverage-cliff.md create mode 100644 entities/health/medicare-glp1-bridge-program.md diff --git a/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md index 80c053707..739a327a3 100644 --- a/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md +++ b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md @@ -25,3 +25,10 @@ The Lancet frames the GLP-1 equity problem as structural policy failure, not mar **Source:** KFF Medicaid GLP-1 analysis, January 2026 Nearly 4 in 10 adults and a quarter of children with Medicaid have obesity, representing tens of millions of potentially eligible beneficiaries. Yet only 13 states (26%) cover GLP-1s for obesity as of January 2026, and four states actively eliminated existing coverage in 2025-2026. The population with highest obesity burden and least ability to pay out-of-pocket faces the most restrictive access, with eligibility now depending primarily on state of residence rather than clinical need. + + +## Extending Evidence + +**Source:** KFF Health Policy analysis of Medicare GLP-1 Bridge (April 2026) + +Medicare GLP-1 Bridge program demonstrates access inversion operates at federal program design level, not just market level. The LIS exclusion means the program structurally denies coverage to the lowest-income Medicare beneficiaries despite nominal eligibility. The $50 copay falls outside Part D cost-sharing structures, making it invisible to LIS subsidies. This is architectural: the demonstration authority operates 'outside' Part D benefit design as an exception to statutory weight-loss drug prohibition. diff --git a/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md index d146f461f..d8af734ba 100644 --- a/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md +++ b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md @@ -10,16 +10,10 @@ agent: vida scope: causal sourcer: Tzang et al. (Lancet eClinicalMedicine) related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"] -related: -- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks -reweave_edges: -- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09 -- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12 -- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14 -supports: -- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales -challenges: -- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement +related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"] +reweave_edges: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09", "GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14"] +supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"] +challenges: ["Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement"] --- # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation @@ -31,3 +25,10 @@ Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP **Source:** WHO December 2025 guideline conditional framing WHO's conditional recommendation acknowledges 'limited long-term evidence' and 'durability of effects unclear' as reasons for not issuing a strong recommendation. The guideline's caution about discontinuation effects aligns with the 28-52 week reversal timeline documented in clinical trials. + + +## Challenging Evidence + +**Source:** KFF Health Policy analysis of Medicare GLP-1 Bridge timeline (April 2026) + +Medicare GLP-1 Bridge program provides only six months of coverage (July-December 2026), directly conflicting with chronic treatment requirement. Beneficiaries wanting 2027 continuation must switch Part D plans during open enrollment, creating structural treatment discontinuity. The temporary demonstration authority architecture is incompatible with the clinical reality of chronic medication requiring continuous use. diff --git a/domains/health/medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access.md b/domains/health/medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access.md new file mode 100644 index 000000000..47ef3f300 --- /dev/null +++ b/domains/health/medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access.md @@ -0,0 +1,18 @@ +--- +type: claim +domain: health +description: The $50 copay falls outside Part D cost-sharing structures making it invisible to LIS subsidies, creating a legal architecture that says yes to low-income eligibility while the payment mechanism says no +confidence: experimental +source: KFF Health Policy analysis of CMS Medicare GLP-1 Bridge program documents (April 2026) +created: 2026-04-22 +title: Medicare GLP-1 Bridge program structurally excludes Low-Income Subsidy beneficiaries through cost-sharing architecture that operates outside Part D benefit design +agent: vida +sourced_from: health/2026-04-22-kff-medicare-glp1-bridge-lis-exclusion.md +scope: structural +sourcer: KFF Health Policy +related: ["medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi"] +--- + +# Medicare GLP-1 Bridge program structurally excludes Low-Income Subsidy beneficiaries through cost-sharing architecture that operates outside Part D benefit design + +The Medicare GLP-1 Bridge program (July-December 2026) covers Wegovy and Zepbound at a fixed $50 copayment for eligible Part D beneficiaries. However, Low-Income Subsidy (LIS) cost-sharing subsidies explicitly do not apply to GLP-1 prescriptions under this program. This is not an oversight but reflects the novel legal architecture: the program operates 'outside' standard Part D benefit structures as a demonstration authority exception to Medicare's statutory prohibition on weight-loss drug coverage. The $50 copay does not count toward the Part D deductible or the $2,100 out-of-pocket cap, creating a segregated benefit structure. The result is that the program's eligibility criteria (BMI ≥35 alone, or ≥27 with clinical criteria) include low-income patients, but the cost-sharing architecture structurally excludes them. This represents program-level reproduction of the access hierarchy: federal expansion that fails the most access-constrained population by design, not by market failure. diff --git a/domains/health/medicare-glp1-bridge-temporary-architecture-creates-2027-coverage-cliff.md b/domains/health/medicare-glp1-bridge-temporary-architecture-creates-2027-coverage-cliff.md new file mode 100644 index 000000000..a65140f7c --- /dev/null +++ b/domains/health/medicare-glp1-bridge-temporary-architecture-creates-2027-coverage-cliff.md @@ -0,0 +1,19 @@ +--- +type: claim +domain: health +description: The Bridge program ends December 31, 2026, forcing beneficiaries who want continued coverage to identify and switch to plans offering GLP-1 coverage during open enrollment, creating treatment disruption risk +confidence: experimental +source: KFF Health Policy analysis of Medicare GLP-1 Bridge program timeline (April 2026) +created: 2026-04-22 +title: Medicare GLP-1 Bridge six-month duration creates coverage discontinuity requiring beneficiaries to switch Part D plans mid-treatment for 2027 continuation +agent: vida +sourced_from: health/2026-04-22-kff-medicare-glp1-bridge-lis-exclusion.md +scope: structural +sourcer: KFF Health Policy +challenges: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"] +related: ["vbc-requires-enrollment-stability-as-structural-precondition-because-prevention-roi-depends-on-multi-year-attribution", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-long-term-persistence-ceiling-14-percent-year-two"] +--- + +# Medicare GLP-1 Bridge six-month duration creates coverage discontinuity requiring beneficiaries to switch Part D plans mid-treatment for 2027 continuation + +The Medicare GLP-1 Bridge program operates only from July 1 to December 31, 2026. Beneficiaries who begin treatment during this window and want continued coverage in 2027 must switch Part D plans during open enrollment. This creates a structural coverage cliff: the demonstration program provides temporary access but no transition pathway. The longer BALANCE Model demonstration launches in Medicare Part D in January 2027, but beneficiaries must actively identify plans participating in that model and switch during the enrollment window. For a chronic medication requiring continuous treatment (as established by GLP-1 discontinuation evidence showing metabolic benefit reversal within 28-52 weeks), this six-month temporary access followed by required plan switching creates treatment disruption risk. The architecture reflects the demonstration authority's temporary exception status rather than durable policy change, but the clinical reality of chronic treatment makes temporary access operationally problematic. diff --git a/entities/health/medicare-glp1-bridge-program.md b/entities/health/medicare-glp1-bridge-program.md new file mode 100644 index 000000000..fce387da5 --- /dev/null +++ b/entities/health/medicare-glp1-bridge-program.md @@ -0,0 +1,57 @@ +--- +type: entity +entity_type: research_program +name: Medicare GLP-1 Bridge Program +domain: health +status: active +start_date: 2026-07-01 +end_date: 2026-12-31 +parent_organization: Centers for Medicare & Medicaid Services (CMS) +--- + +# Medicare GLP-1 Bridge Program + +## Overview + +Temporary Medicare demonstration program providing coverage for GLP-1 receptor agonists (Wegovy, Zepbound) for obesity treatment from July 1 to December 31, 2026. Operates as an exception to Medicare's statutory prohibition on weight-loss drug coverage. + +## Program Structure + +**Eligibility:** +- BMI ≥35 alone, OR +- BMI ≥27 with clinical criteria +- Must be enrolled in Medicare Part D + +**Cost-sharing:** +- Fixed $50 copayment per prescription +- Copay does NOT count toward Part D deductible +- Copay does NOT count toward $2,100 out-of-pocket cap +- Low-Income Subsidy (LIS) cost-sharing subsidies do NOT apply + +**Coverage:** +- Wegovy (semaglutide) +- Zepbound (tirzepatide) + +## Structural Issues + +**LIS Exclusion:** The program operates outside standard Part D benefit structures, making the $50 copay invisible to Low-Income Subsidy mechanisms. This structurally excludes the lowest-income Medicare beneficiaries despite nominal eligibility. + +**Temporary Duration:** Six-month program creates coverage cliff. Beneficiaries wanting 2027 continuation must switch Part D plans during open enrollment to plans participating in the BALANCE Model demonstration (launches January 2027). + +**Eligible Population:** Approximately 14 million Medicare beneficiaries had diagnosed overweight/obesity in 2020, representing potential eligible pool. + +## Legal Architecture + +Operates under CMS demonstration authority as temporary exception to Social Security Act Section 1862(a)(1)(A), which prohibits Medicare coverage of drugs for weight loss. This demonstration status explains the segregated benefit structure and LIS incompatibility. + +## Related Programs + +- **BALANCE Model (Medicare Part D):** Launches January 2027, longer-term demonstration +- **BALANCE Model (Medicaid):** Launches May 2026 + +## Timeline + +- **2026-04** — Program details announced by CMS +- **2026-07-01** — Coverage begins +- **2026-12-31** — Coverage ends +- **2027-01** — BALANCE Model begins (requires plan switching during open enrollment) \ No newline at end of file